Myo-Inositol for Fertility and PCOS: What the Evidence Really Shows

Myo-inositol is a naturally occurring sugar alcohol that functions as a second messenger in insulin signalling pathways — and it has become one of the most widely discussed supplements in the polycystic ovary syndrome (PCOS) and fertility space.¹ Research suggests that myo-inositol may improve insulin sensitivity, support more regular ovulation, and influence oocyte quality in women with PCOS, though the strength of evidence varies across these outcomes.²

If you have PCOS and are trying to conceive, you have likely encountered myo-inositol in online forums, supplement recommendations, or even from your healthcare provider. This article examines what myo-inositol actually does in the body, what clinical research tells us about its effects on fertility, how it compares with other treatments, and what you should realistically expect. Every claim is grounded in peer-reviewed evidence, and we will be transparent about where the science is strong and where it remains uncertain.

What Is Myo-Inositol and How Does It Relate to Fertility?

Myo-inositol is one of nine naturally occurring forms (stereoisomers) of inositol, a cyclic sugar alcohol found in foods such as fruits, beans, grains, and nuts. Although sometimes referred to as “vitamin B8,” myo-inositol is not technically a vitamin because the body can synthesise it from glucose.¹ It is the most abundant form of inositol in human cells and plays a critical role in cellular signalling.

Here is the connection to fertility: once myo-inositol enters a cell, it is incorporated into phosphatidylinositol, which is then converted to inositol triphosphate (IP3) — a key intracellular second messenger.³ This pathway mediates the actions of several hormones that are directly relevant to reproduction, including insulin, follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH).³

In practical terms, myo-inositol helps your cells respond properly to insulin. When insulin signalling works efficiently, the ovaries receive appropriate hormonal cues, androgen production normalises, and the conditions for regular ovulation improve. This is why myo-inositol has attracted particular interest in PCOS and fertility — a condition where insulin resistance drives many of the hormonal disruptions that prevent ovulation.

How Does Myo-Inositol Work in PCOS Specifically?

Myo-inositol targets several interconnected pathways that are disrupted in PCOS. Understanding these mechanisms helps explain why it can influence metabolic markers, hormone levels, and ovarian function — while also clarifying the limits of what it can achieve.

Insulin Sensitisation and the AMPK Pathway

Insulin resistance affects an estimated 50–70% of women with PCOS, regardless of body weight.⁴ When cells become less responsive to insulin, the pancreas compensates by producing more insulin (hyperinsulinaemia). This excess insulin directly stimulates the ovaries to produce androgens — male-type hormones such as testosterone — which disrupt follicle development and ovulation.⁵

Research indicates that myo-inositol improves insulin sensitivity through activation of the AMPK (adenosine monophosphate-activated protein kinase) pathway and enhanced GLUT-4 glucose transporter expression.⁶ A 2017 meta-analysis of randomised controlled trials found that myo-inositol supplementation significantly reduced fasting insulin levels and the homeostasis model assessment of insulin resistance (HOMA-IR) index in women with PCOS.²

Androgen Reduction

By improving insulin sensitivity and reducing circulating insulin levels, myo-inositol has a downstream effect on androgen production. One double-blind trial reported that serum total testosterone decreased significantly — from 99.5 ng/dL to 34.8 ng/dL — after myo-inositol treatment, with free testosterone dropping from 0.85 to 0.24 ng/dL.⁷ A meta-analysis also identified a trend toward testosterone reduction, alongside increased sex hormone-binding globulin (SHBG), which further reduces the amount of biologically active testosterone.²

Ovarian Function and FSH Signalling

Beyond insulin, myo-inositol acts as a second messenger for FSH in granulosa cells — the cells surrounding the developing egg within each ovarian follicle.⁸ Adequate myo-inositol levels in follicular fluid appear to support proper follicle maturation and oocyte quality. Studies have found that higher concentrations of myo-inositol in follicular fluid correlate with better oocyte grades.⁹

What Does the Research Say About Myo-Inositol and Fertility Outcomes?

This is where transparency matters. The evidence for myo-inositol varies depending on which outcome you are looking at — and the most recent systematic reviews have highlighted important limitations.

Metabolic and Hormonal Improvements: Strong Evidence

The clearest evidence supports myo-inositol’s effects on metabolic and hormonal markers. A meta-analysis of randomised controlled trials found significant improvements in fasting insulin, HOMA-IR, total testosterone, and SHBG levels.² These changes are clinically meaningful because insulin resistance and hyperandrogenism are the primary drivers of anovulation in PCOS.

Ovulation and Menstrual Regularity: Moderate Evidence

Observational studies have reported that up to 70% of women with PCOS restored ovulation after myo-inositol supplementation.¹⁰ However, controlled trials present a more nuanced picture. A systematic review informing the 2023 international PCOS guidelines update found some evidence supporting improved menstrual regularity but noted that the quality of evidence was low to moderate.¹¹ Importantly, head-to-head trials comparing myo-inositol with metformin — the established insulin sensitiser for PCOS — found similar improvements in ovulation rates, with myo-inositol offering a more favourable side-effect profile.¹²

Pregnancy and Live Birth Rates: Limited Evidence

Here is the honest assessment: when it comes to the outcome that matters most — pregnancy and live birth rates — the evidence remains limited and inconclusive. The 2023 international evidence-based PCOS guidelines specifically noted that myo-inositol supplementation is not recommended as a stand-alone fertility treatment.¹¹ Four randomised trials comparing myo-inositol with metformin found no significant differences in clinical pregnancy rates between the two.¹¹

This does not mean myo-inositol is ineffective. It means the evidence base is not yet strong enough to recommend it as a primary fertility treatment. The distinction matters: myo-inositol may be most valuable as a complementary approach alongside lifestyle changes and, when needed, medical ovulation induction with letrozole or clomiphene.

IVF and Assisted Reproduction: Emerging Evidence

A 2025 systematic review and meta-analysis examining myo-inositol supplementation prior to IVF found that pre-treatment may improve the mature oocyte (MII) rate in women with PCOS.¹³ The EGOI-PCOS expert group published a position statement in 2025 concluding that myo-inositol administered for three months prior to ovarian stimulation may reduce FSH doses required and improve oocyte and embryo quality.¹⁴ These findings are promising but require further confirmation in larger trials.

What Is the 40:1 Myo-Inositol to D-Chiro-Inositol Ratio and Why Does It Matter?

You will often see myo-inositol supplements that combine it with D-chiro-inositol (DCI) in a specific 40:1 ratio. This is not arbitrary marketing — it reflects genuine physiological science, though with some important caveats.

In healthy individuals, the plasma ratio of myo-inositol to D-chiro-inositol is approximately 40:1.¹⁵ The body converts myo-inositol into D-chiro-inositol through an enzyme called epimerase, and each form has distinct roles: myo-inositol primarily mediates glucose uptake in cells, while D-chiro-inositol mediates glycogen synthesis in the liver and muscles.¹⁵

Here is the complication in PCOS — a phenomenon researchers call the “DCI paradox.” In insulin-resistant tissues (muscle, fat, liver), the conversion of myo-inositol to DCI is impaired, leading to DCI deficiency in those tissues. But in the ovaries, the opposite happens: excess insulin actually increases DCI levels in follicular fluid.¹⁶ High DCI concentrations in the ovary appear to be harmful — they may impair oocyte quality and reduce the responsiveness of granulosa cells to FSH signalling.¹⁶

In healthy follicular fluid, the myo-inositol to DCI ratio is approximately 100:1 — even higher than plasma.⁹ When this ratio drops due to excessive DCI, egg quality may suffer. This is why taking high doses of DCI alone, without myo-inositol, could theoretically worsen ovarian outcomes in PCOS — a concern supported by some clinical observations.¹⁶

A 2019 clinical study comparing different ratios found that the 40:1 ratio was most effective at restoring ovulation in women with PCOS, outperforming both myo-inositol alone and other ratios.¹⁵ A 2024 study further confirmed that the 40:1 ratio improved hormonal and metabolic profiles in women with Phenotype A PCOS.¹⁷

How Does Myo-Inositol Compare with Metformin for PCOS?

Metformin has been used as an insulin sensitiser in PCOS management for over two decades, while myo-inositol is a more recent entrant. Head-to-head comparison is a common question for women with PCOS who are exploring their options.

Several randomised controlled trials have directly compared the two. A systematic review found that myo-inositol and metformin produced similar improvements in insulin sensitivity, menstrual regularity, and hormonal profiles.¹² Neither showed a clear advantage in pregnancy rates over the other.¹¹

The key practical difference lies in tolerability. Metformin commonly causes gastrointestinal side effects — nausea, diarrhoea, and abdominal discomfort — particularly during the dose escalation phase, affecting up to 25% of users.¹² Myo-inositol, by contrast, has minimal side effects even at higher doses, with only occasional mild gastrointestinal symptoms reported.¹⁸

It is important to note that metformin has a much larger evidence base, longer clinical track record, and is specifically mentioned in international PCOS treatment guidelines. Myo-inositol is not a like-for-like replacement for metformin in all contexts. For women who cannot tolerate metformin, or who prefer a supplement-based approach alongside lifestyle changes, myo-inositol offers a reasonable alternative — but this decision should be made with your healthcare provider.

Can Myo-Inositol Help Male Fertility?

While most research focuses on women with PCOS, emerging evidence suggests myo-inositol may also benefit male reproductive health. Myo-inositol is naturally present in high concentrations in seminal fluid, where it plays a role in sperm motility and capacitation — the final maturation step sperm undergo before fertilisation.¹⁹

A limited number of studies have investigated myo-inositol supplementation in men with abnormal sperm parameters. Preliminary findings suggest improvements in sperm concentration, motility, and morphology, though the evidence base is small and further randomised controlled trials are needed.¹⁹ For couples where both partners have contributing factors, myo-inositol supplementation for the male partner is an area worth discussing with a healthcare provider — particularly given its excellent safety profile.

What Is the Recommended Dosage and How Long Does It Take to Work?

The most widely studied dose of myo-inositol for PCOS is 4 g per day, divided into two doses of 2 g each — typically taken morning and evening.¹⁴ When combined with D-chiro-inositol, the standard protocol is 4 g myo-inositol plus 100 mg D-chiro-inositol daily, maintaining the 40:1 ratio.

Most clinical trials supplemented with 200 mcg of folic acid alongside inositol, which is standard preconception practice regardless of inositol use. Folic acid is independently recommended for all women planning pregnancy.

Timeline for Results

Understanding the biology helps set realistic expectations:

• Metabolic markers (fasting insulin, HOMA-IR): Improvements may appear within 6–12 weeks of consistent supplementation.²
• Menstrual regularity: Most women who respond will notice cycle changes within 3–6 months.¹⁰
• Ovulation restoration: Follicular development takes approximately 100 days from the primordial stage to ovulation, so allowing at least 3 months is biologically reasonable.
• Oocyte quality improvements: If you are preparing for IVF, the EGOI-PCOS expert group recommends beginning supplementation at least 3 months before ovarian stimulation.¹⁴

These timelines reflect the biology of follicle development and insulin sensitisation — not limitations of the supplement itself. Consistency matters more than dose escalation.

Is Myo-Inositol Safe? What Are the Side Effects?

Myo-inositol has an excellent safety record. Doses up to 12 g/day have been used in clinical research without serious adverse effects reported.¹⁸ At the standard 4 g/day dose for PCOS, side effects are uncommon and typically mild:

• Mild gastrointestinal discomfort (nausea, bloating, loose stools) — usually transient
• Possible mild headache in the first few days of supplementation
• No significant drug interactions reported at standard doses

However, myo-inositol does interact with the TSH signalling pathway.³ Women with thyroid conditions — particularly hypothyroidism — should inform their healthcare provider before starting supplementation, as adjustments to thyroid medication may be needed.

Myo-inositol is not recommended as a replacement for prescribed fertility medications. If your healthcare provider has recommended letrozole, clomiphene, or gonadotropins for ovulation induction, myo-inositol is best used as a complementary approach, not an alternative.

Frequently Asked Questions

Does myo-inositol help you get pregnant with PCOS?

Myo-inositol may improve conditions that support conception — better insulin sensitivity, lower androgens, and more regular ovulation — but current evidence does not confirm it directly increases pregnancy rates as a stand-alone treatment. It is best used alongside lifestyle modifications and medical treatment when appropriate.¹¹

How long should I take myo-inositol before expecting results?

Most women notice improvements in menstrual regularity within 3–6 months. Metabolic markers like fasting insulin may improve within 6–12 weeks. The 100-day follicular development cycle means that at least 3 months is needed for potential effects on egg quality.

Is myo-inositol better than metformin for PCOS?

Head-to-head trials show similar metabolic and hormonal improvements. Myo-inositol has fewer side effects (especially gastrointestinal), but metformin has a stronger evidence base and is included in international guidelines.¹² The choice depends on your individual situation and should be discussed with your healthcare provider.

Should I take myo-inositol alone or with D-chiro-inositol?

Research supports combining the two in a 40:1 ratio (4 g MI + 100 mg DCI), which mirrors the body’s natural plasma ratio and has been shown to outperform myo-inositol alone for ovulation restoration.¹⁵ Taking D-chiro-inositol alone in high doses is not recommended, as excess DCI in the ovaries may impair egg quality.

Can I take myo-inositol if I don’t have PCOS?

Myo-inositol is generally safe, and some IVF research has explored its use in non-PCOS populations. However, the strongest evidence applies to women with PCOS-related insulin resistance. If you do not have PCOS, discuss with your healthcare provider whether it is appropriate for your situation.¹³

Can my male partner take myo-inositol too?

Preliminary research suggests myo-inositol may support sperm motility and quality, but the evidence is limited. Given its safety profile, it may be worth discussing with a healthcare provider for couples where male factor is a concern.¹⁹

Does myo-inositol interact with fertility medications?

No significant interactions have been reported between myo-inositol and common fertility medications (letrozole, clomiphene, gonadotropins). It may actually complement these treatments by improving ovarian response.¹⁴ Always inform your fertility specialist about all supplements you are taking.

The Bottom Line

Myo-inositol is a well-tolerated, evidence-informed supplement that addresses several of the core metabolic and hormonal disruptions underlying PCOS. The strongest evidence supports its effects on insulin sensitivity, androgen levels, and menstrual regularity. For fertility specifically, it is best understood as a supportive tool — one that may create more favourable conditions for ovulation and conception, rather than a stand-alone fertility treatment.

If you have PCOS and are trying to conceive, myo-inositol in a 40:1 combination with D-chiro-inositol (4 g + 100 mg daily) is a reasonable, low-risk addition to a comprehensive approach that includes dietary optimisation, regular physical activity, and appropriate medical support. Allow at least 3 months for meaningful changes, and work with your healthcare provider to determine whether myo-inositol fits within your overall fertility plan.

Boost Your Fertility with FertilitySmart

Supporting your fertility with PCOS involves a combination of the right nutrition, consistent lifestyle habits, and evidence-based supplementation. Myo-inositol is one piece of a larger picture that includes optimising your overall nutrient intake.

At FertilitySmart, we offer both fertility supplements for women and fertility supplements for men that contain key ingredients for those trying to conceive, including CoQ10, folic acid, and a range of vitamins and minerals that support reproductive health. Try our supplements today to boost your fertility, and explore our site to learn about more ways to increase ovulation naturally.

Citations

1. Bevilacqua A, Bizzarri M. Myo-Inositol and Its Derivatives: Their Roles in the Challenges of Infertility. Biology. 2024;13(11):936. doi.org/10.3390/biology13110936
2. Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017;6(8):647–658. doi.org/10.1530/EC-17-0243
3. Chhetri DR. Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases. Frontiers in Pharmacology. 2019;10:1172. doi.org/10.3389/fphar.2019.01172
4. Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction. 2013;28(3):777–784. doi.org/10.1093/humrep/des463
5. Diamanti-Kandarakis E, Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications. Endocrine Reviews. 2012;33(6):981–1030. doi.org/10.1210/er.2011-1034
6. Cabrera-Cruz H, Oróstica L, Plaza-Parrochia F, et al. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. American Journal of Physiology-Endocrinology and Metabolism. 2020;318(2):E237–E248. doi.org/10.1152/ajpendo.00162.2019
7. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24(3):139–144. doi.org/10.1080/09513590801893232
8. Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecological Endocrinology. 2015;31(7):501–505. doi.org/10.3109/09513590.2015.1054802
9. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reproduction. 2002;17(6):1591–1596. doi.org/10.1093/humrep/17.6.1591
10. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences. 2007;11(5):347–354. pubmed.ncbi.nlm.nih.gov/18074942
11. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 2023;108(10):2447–2469. doi.org/10.1210/clinem/dgad463
12. Le Donne M, Metro D, Alibrandi A, Papa M, Benvenga S. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences. 2019;23(5):2293–2301. pubmed.ncbi.nlm.nih.gov/30915778
13. Zhang Y, Li C, Zhang L, et al. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Frontiers in Endocrinology. 2025;16:1520362. doi.org/10.3389/fendo.2025.1520362
14. Wdowiak A, Bien A, Szymanski R, et al. The Clinical Use of Myo-Inositol in IVF-ET: A Position Statement from the Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS). Journal of Clinical Medicine. 2025;14(2):558. doi.org/10.3390/jcm14020558
15. Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512–5521. doi.org/10.26355/eurrev_201906_18223
16. Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinemia Alters Myoinositol to D-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reproductive Sciences. 2014;21(7):854–858. doi.org/10.1177/1933719113518985
17. Montanino Oliva M, Busnelli A, Cimadomo D, et al. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with PCOS. Gynecologic and Obstetric Investigation. 2024;89(2):131–140. doi.org/10.1159/000535764
18. Carlomagno G, Unfer V. Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences. 2011;15(8):931–936. pubmed.ncbi.nlm.nih.gov/21845803
19. Condorelli RA, La Vignera S, Bellanca S, Vicari E, Calogero AE. Myoinositol: does it improve sperm mitochondrial function and sperm motility? Urology. 2012;79(6):1290–1295. doi.org/10.1016/j.urology.2012.03.005

Marina Carter

Fertility Health Writer at FertilitySmart

Marina Carter is a specialist health writer with nearly a decade of experience in reproductive health, fertility nutrition, and evidence-based conception support. She has authored over 30 in-depth articles for FertilitySmart, translating peer-reviewed research into clear, practical guidance for individuals and couples on their fertility journey. Read full bio →